BD BBL™ Sensi-Disc™ Piperacillin/Tazobactam 100/10 µg 231691Recalls & reported problems
Becton, Dickinson And Company · BD BBL™ Sensi-Disc™ Piperacillin/Tazobactam 100/10 µg · Class 2
All models of BD BBL Sensi-Disc Piperacillin/Tazobactam 100/10 µg (2)
Data updated Oct 18, 2026 from official FDA records · Editorial policy
1 open recall names this device. See the recall details and contact the manufacturer or your healthcare provider.
- Adverse event reports
- 1
- Deaths reported
- 0
- Injuries reported
- 0
- Recalls naming it
- 1
Summary
The FDA's MAUDE database contains 1 adverse event report that list this exact device (DI 00382902316916), received between Apr 24, 2024 and Apr 24, 2024 — classified as 1 malfunction.
The most frequently reported specific device problem is “Inaccurate Information” (1 report).
1 FDA recall record name this device's identifier, 1 still open.
Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 18, 2026.
Reports received per month
Recalls naming this device
- Jan 8, 2024Class IIOpen, Classified
There is a possibility of reproducibility, accuracy, and/or QC failures in antibiotic susceptibility testing (AST) for H. influenzae. This may cause product discard, delayed results, or additional adverse diagnostic outcomes, such as a delay in diagnosis, the selection of inappropriate antibiotics, or extended duration of antibiotic exposure and the treatment process.
Z-1037-2024 · Root cause: Process control · Recall details · FDA record ↗
Most reported problems
Device problems
- Inaccurate Information1
Patient problems
- No Clinical Signs, Symptoms or Conditions1
Recent adverse event reports
The 1 most recent of 1 reports, in the reporter's own words as published by the FDA.
MalfunctionApr 24, 2024Inaccurate Information; Inaccurate Information
IT WAS REPORTED THAT THE PRODUCT INSERT FOR BD BBL¿ SENSI-DISC¿ PIPERACILLIN/TAZOBACTAM - 100/10 G CONTAINED INCORRECT BREAKPOINT INFORMATION FOR PIPERACILLIN/TAZOBACTAM. THERE WAS NO REPORT OF PATIENT IMPACT.
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 19173661 ↗
Other SUSCEPTIBILITY TEST DISCS, ANTIMICROBIAL devices
- BD BBL Sensi-Disc Ampicillin 2 ug 231263Becton, Dickinson And Company · SUSCEPTIBILITY TEST DISCS, ANTIMICROBIAL2 recalls0 reports
- BD BBL™ Sensi-Disc™ Ciprofloxacin 5 µg 231658Becton, Dickinson And Company · SUSCEPTIBILITY TEST DISCS, ANTIMICROBIAL1 recall2 reports
- BD BBL™ Sensi-Disc™ Ceftazidime 30 µg 231633Becton, Dickinson And Company · SUSCEPTIBILITY TEST DISCS, ANTIMICROBIAL1 recall1 report
- BD BBL™ Sensi-Disc™ Levofloxacin 5 µg 231706Becton, Dickinson And Company · SUSCEPTIBILITY TEST DISCS, ANTIMICROBIAL1 recall1 report
- BD BBL™ Sensi-Disc™ Cefepime 30 µg 231696Becton, Dickinson And Company · SUSCEPTIBILITY TEST DISCS, ANTIMICROBIAL1 recall1 report
- BD BBL™ Sensi-Disc™ Chloramphenicol 30 µg 231274Becton, Dickinson And Company · SUSCEPTIBILITY TEST DISCS, ANTIMICROBIAL1 recall0 reports
- BD BBL™ Sensi-Disc™ Cefotaxime 30 µg 231607Becton, Dickinson And Company · SUSCEPTIBILITY TEST DISCS, ANTIMICROBIAL1 recall0 reports
- BD BBL™ Sensi-Disc™ Chloramphenicol - 30 µg 230733Becton, Dickinson And Company · SUSCEPTIBILITY TEST DISCS, ANTIMICROBIAL1 recall0 reports
Sources and updates
- Device record: FDA GUDID, file dated Oct 13, 2026 · View this device in AccessGUDID ↗
- Adverse event reports: FDA MAUDE, file dated Oct 14, 2026 · each report above links to its original FDA record
- Recalls: FDA Medical Device Recalls, file dated Oct 16, 2026 · each recall links to the FDA recall notice
- Page last rebuilt: Oct 18, 2026. Data downloaded through openFDA, which notes it is not validated for clinical or regulatory use.
How reports and recalls are matched · Editorial policy · Report an error on this page